GlassScriptPhysician profile
David L Liporace
NPI 1184610818
$183,390.25
in general payments reported to CMS, 2019-2025
59 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $48K · 2021: $24K · 2022: $18K · 2023: $15K · 2024: $25K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Honoraria: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $5,326 · Travel and Lodging: $3,792 · Education: $5.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,850.50 |
| Honoraria | $17,562.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,796.00 |
| Food and Beverage | $5,325.98 |
| Travel and Lodging | $3,791.73 |
| Education | $5.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $42,269.71 | 2019-2021 | |
| Axsome Therapeutics, INC. | $38,850.18 | 2022-2025 | Auvelity, Sunosi |
| Abbvie INC. | $32,197.61 | 2019-2025 | |
| Gilead Sciences, INC. | $17,869.93 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $13,499.15 | 2019-2023 | Uzedy |
| Amgen INC. | $11,471.75 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $5,333.26 | 2019-2023 | Trintellix |
| Pfizer INC. | $4,902.95 | 2019-2025 | |
| Biogen, INC. | $2,196.00 | 2023 | |
| Janssen Pharmaceuticals, INC | $2,108.34 | 2019-2023 | Xarelto |
| Nevro Corp. | $1,990.67 | 2022-2023 | Senza |
| Novo Nordisk INC | $924.04 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $908.04 | 2019-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $845.70 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $714.64 | 2019-2023 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Liporace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.